✦ LIBER ✦

Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma

✍ Scribed by Wataru Obara; Yoichi Mizutani; Chikara Oyama; Hideyuki Akaza; Nobuhisa Ishii; Kenjiro Kohri; Mikio Namiki; Akihiko Okuyama; Hiroki Shima; Masayoshi Yokoyama; Taro Shuin; Tsuneharu Miki; Yoshiyuki Watanabe; Tomoaki Fujioka

Book ID: 108977762
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 262 KB
Volume: 15
Category: Article
ISSN: 0919-8172
DOI: 10.1111/j.1442-2042.2008.02086.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of sorafenib in combinatio

Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma

✍ Masashi Niwakawa, Katsuyoshi Hashine, Raizo Yamaguchi, Hirofumi Fujii, Yasuo Ham 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 359 KB

Erratum to: Phase I trial of sorafenib i

Erratum to: Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma

✍ Masashi Niwakawa, Katsuyoshi Hashine, Raizo Yamaguchi, Hirofumi Fujii, Yasuo Ham 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 65 KB

Clinical outcome of combined immunothera

Clinical outcome of combined immunotherapy with interferon-α and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma

✍ Hideaki Miyake; Toshifumi Kurahashi; Atsushi Takenaka; Taka-aki Inoue; Masato Fu 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 334 KB

MP-16.20: Thalidomide in combination wit

MP-16.20: Thalidomide in combination with interleukin-2 for patients with metastatic renal cell carcinoma refractory to prior IL-2 and alpha-interferon treatment

✍ R. Shiroki; S. Mori; S. Miyakawa; M. Ichino; M. Hirano; M. Kusaka; K. Hayakawa; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Recombinant interferon-alpha combined wi

Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma reduced toxicity without reduction of the response rate—a phase II study

✍ Sophie D. Fosså; Ragnhild Gunderson; Brit Moe 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB 👁 2 views

Clinical outcome of combined immunothera

Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-α for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report

✍ Hideaki Miyake; Isao Hara; Iori Sakai; Ken-ichi Harada; Taka-aki Inoue; Hiroshi 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 244 KB